Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients

The European Union’s Committee for Medicinal Products for Human Use (CHMP) declined to endorse Roche's application for Sarepta Therapeutics' gene therapy Elevidys for ambulatory Duchenne muscular dystrophy patients, a decision analysts anticipate will reduce Sarepta's future milestone and royalty payments from Roche. This negative opinion follows a safety scandal involving multiple patient deaths linked to the gene therapy's vector technology, leading to shipment suspensions and a black box warning. While Roche will continue discussions with the EMA, the final European Commission decision within 67 days will determine the therapy's market access amidst heightened safety scrutiny.

Analysis

The European Union's Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on approving Sarepta Therapeutics' (SRPT) gene therapy, Elevidys, a decision that directly threatens future milestone and royalty revenues for SRPT from its regional partner, Roche (RHHBY). According to William Blair analysts, this outcome was "unfortunate but unsurprising" and delivers a financial blow to Sarepta. The regulatory setback is compounded by a significant safety crisis surrounding the therapy's adeno-associated virus (AAV) vector technology. This crisis includes three recent patient deaths—two involving Elevidys and a third linked to a different investigational therapy using the same vector—which prompted Sarepta to add a black box warning and, after initial resistance, comply with an FDA request to suspend all shipments. While Roche has also halted deliveries for non-ambulatory patients in certain regions, it maintains that the benefit-risk profile for the ambulatory population is positive. The CHMP's recommendation is not final; a legally binding decision from the European Commission is expected within 67 days, leaving a narrow window for Roche to negotiate a path forward with the European Medicines Agency.

Key Decisions for Investors

• Investors in Sarepta (SRPT) should reassess future revenue forecasts, as the negative EU opinion and the severe safety issues with its core AAV vector technology create significant headwinds for both Elevidys and potentially other pipeline assets.
• For Roche (RHHBY), while the negative opinion jeopardizes its $1.15 billion upfront investment in Elevidys, the impact is moderated by its diversified portfolio; the key event to monitor is the final European Commission decision within the next 67 days.
• Traders should anticipate heightened volatility for SRPT as the market awaits the final European Commission ruling and any further disclosures from the FDA or the company regarding the ongoing safety investigation into the AAV vector platform.